In the videos below, Dr. Andrew Chi talks about ONC201 and his Phase II – Adults with Recurrent H3 K27M High-grade Glioma (NCT03295396) at NYU Langone. H3 K27M-mutant gliomas are known to overexpress DRD2, the target that ONC201 utilizes to drive its anti-cancer effects. Andrew S. Chi, MD PhD, Chief of Neuro-Oncology and the Codirector of
“Immune cell activation in the tumor and inhibition of metastasis with an oral, infrequently administered and well tolerated small molecule provides an attractive treatment option for patients. Immune activation is recognized as an important requirement to achieve durable and complete remissions in conjunction with standard-of-care therapies,” said El-Deiry. “We discovered ONC201 through its ability to
In the videos below, Dr. Peter Anderson talks about ONC201 and his Phase II – Neuroendocrine Tumors (NCT03034200) at The Cleveland Clinic. The clinical trial is evaluating ONC201 in patients with neuroendocrine tumors. These tumors are known to overexpress DRD2, the target that ONC201 utilizes to drive its anti-cancer effects. Dr. Peter Anderson is the
Frontida BioPharm has made an equity investment in Oncoceutics as part of a product development and commercialization agreement to advance the company’s lead compound. The full article can be found here.
Business Development